- Home
- BXSL vs ROIV Comparison
BXSL vs ROIV Comparison
Compare BXSL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BXSL | ROIV |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BXSL | ROIV |
|---|---|---|
| Price | $27.80 | $22.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $29.38 | $24.31 |
| AVG Volume (30 Days) | 1.5M | ★ 7.9M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | ★ 11.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $1,413,784,000.00 | $20,329,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $0.28 | $376.94 |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | ★ 10.58 | N/A |
| 52 Week Low | $24.85 | $8.73 |
| 52 Week High | $34.64 | $23.47 |
Technical Indicators
Market Signals| Indicator | BXSL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 71.54 |
| Support Level | $28.03 | $20.14 |
| Resistance Level | $28.59 | $21.48 |
| Average True Range (ATR) | 0.41 | 0.79 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 43.57 | 85.33 |
Price Performance
Historical ComparisonAbout BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.